183322-18-1
183322-18-1
Chemical Structure
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline
- CAS No.: 183322-18-1
- Formula:C14H17ClN2O4
- Molecular Weight:312.75
IUPAC Name: 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline
InChIKey: ZPJLDMNVDPGZIU-UHFFFAOYSA-N
SMILES: ClC1=NC=NC2=C1C=C(OCCOC)C(OCCOC)=C2
Biological Activity: 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline (Compound 11 and 15) is a building block and synthetic intermediate, which can be used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer agents. 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline can also be used to synthesize EGFR inhibitors, including Erlotinib (HY-50896), with antiproliferative activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline | 99.55% | 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline (Compound 11 and 15) is a building block and synthetic intermediate, which can be used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer agents. 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline can also be used to synthesize EGFR inhibitors, including Erlotinib (HY-50896), with antiproliferative activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Erlotinib Hydrochloride | 99.94% | Erlotinib (CP-358774) Hydrochloride is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib Hydrochloride also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib Hydrochloride blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib Hydrochloride inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, as well as the deposition of fibronectin, α-SMA, collagen and renal injury markers. Erlotinib Hydrochloride is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib Hydrochloride can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, EGFR inhibitor resistance and renal fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Erlotinib-13C6 hydrochloride | Erlotinib-13C6 hydrochloride (CP-358774-13C6 hydrochloride) is the 13C-labeled Erlotinib Hydrochloride (HY-12008). Erlotinib (CP-358774) Hydrochloride is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib Hydrochloride also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib Hydrochloride blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib Hydrochloride inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, as well as the deposition of fibronectin, α-SMA, collagen and renal injury markers. Erlotinib Hydrochloride is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib Hydrochloride can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, EGFR inhibitor resistance and renal fibrosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Quazodine | Quazodine is a Phosphodiesterase (PDE) inhibitor. Quazodine can be used in vascular smooth muscle related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4-Methyl erlotinib (Standard) | ≥98% | 4-Methyl erlotinib (Standard) is the analytical standard of 4-Methyl erlotinib. This product is intended for research and analytical applications. 4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DCDQ | 99.94% | DCDQ is a potent acetylcholinesterase (AChE) inhibitor. DCDQ shows a strong binding affinity with the 4EY7 protein (binding energy: −8.2 kcal/mol). DCDQ is promising for research of Alzheimer's disease (AD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Erlotinib | 99.96% | Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Erlotinib-13C6 | Erlotinib-13C6 (CP-358774-13C6) is the 13C-labeled Erlotinib (HY-50896). Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Erlotinib lactam impurity | 98.50% | Erlotinib lactam impurity (compound 7a) is a precursor of the tyrosine kinase inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
7-(Benzyloxy)-6-methoxyquinazolin-4(3H)-one | 98.62% | 7-(Benzyloxy)-6-methoxyquinazolin-4(3H)-one is a biochemical reagent that can be used as a biological material or organic compound for life science related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ACDQ | 99.73% | ACDQ (4-Amino-2-chloro-6,7-dimethoxyquinazoline) is a pharmaceutical intermediate that can be used for the synthesis of quinazoline-based antibacterial agents. Molecular docking results of ACDQ indicate that it possesses potential acetylcholinesterase inhibitory activity, and it can be applied to Alzheimer's disease-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang G, et al. Isolation of highly pure erlotinib hydrochloride by recrystallization after nucleophilic substitution of an impurity with piperazine[J]. Research on Chemical Intermediates, 2013, 39(6): 2303-2309.
- [2]. Knesl P, et al. Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib. Molecules. 2006 Apr 10;11(4):286-97. [Content Brief]
